{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T22:41:58Z","timestamp":1769208118311,"version":"3.49.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,8,15]],"date-time":"2013-08-15T00:00:00Z","timestamp":1376524800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s10620-013-2820-9","type":"journal-article","created":{"date-parts":[[2013,8,14]],"date-time":"2013-08-14T11:46:02Z","timestamp":1376480762000},"page":"554-563","source":"Crossref","is-referenced-by-count":13,"title":["Optimizing Screening for Tuberculosis and Hepatitis B Prior to Starting Tumor Necrosis Factor-\u03b1 Inhibitors in Crohn\u2019s Disease"],"prefix":"10.1007","volume":"59","author":[{"given":"Mike","family":"van der Have","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bas","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herma H.","family":"Fidder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim D. G.","family":"Belderbos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter D.","family":"Siersema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martijn G. H.","family":"van Oijen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,15]]},"reference":[{"key":"2820_CR1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.crohns.2009.02.010","volume":"3","author":"JF Rahier","year":"2009","unstructured":"Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3:47\u201391.","journal-title":"J Crohns Colitis"},{"key":"2820_CR2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","volume":"3","author":"A Kornbluth","year":"2010","unstructured":"Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;3:501\u2013523.","journal-title":"Am J Gastroenterol"},{"key":"2820_CR3","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.2010.224154","volume":"60","author":"C Mowat","year":"2011","unstructured":"Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571\u2013607.","journal-title":"Gut"},{"key":"2820_CR4","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.282.7.677","volume":"282","author":"C Dye","year":"1999","unstructured":"Dye C, Scheele S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999;282:677\u2013686.","journal-title":"JAMA"},{"key":"2820_CR5","first-page":"CD008794","volume":"16","author":"JA Singh","year":"2011","unstructured":"Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;16:CD008794.","journal-title":"Cochrane Database Syst Rev"},{"key":"2820_CR6","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098\u20131104.","journal-title":"N Engl J Med"},{"key":"2820_CR7","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","volume":"48","author":"JJ Gomez-Reino","year":"2003","unstructured":"Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk\u2014a multicentre active-surveillance report. Arthr Rheum. 2003;48:2122\u20132127.","journal-title":"Arthr Rheum"},{"key":"2820_CR8","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","volume":"52","author":"J Askling","year":"2005","unstructured":"Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthr Rheum. 2005;52:1986\u20131992.","journal-title":"Arthr Rheum"},{"key":"2820_CR9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","volume":"50","author":"F Wolfe","year":"2004","unstructured":"Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthr Rheum. 2004;50:372\u2013379.","journal-title":"Arthr Rheum"},{"issue":"Supp II","key":"2820_CR10","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/S0168-8278(03)00141-7","volume":"39","author":"MJ Alter","year":"2003","unstructured":"Alter MJ. Epidemiology of hepatitis B in Europe and in worldwide. J Hepatol. 2003;39(Supp II):S64\u2013S69.","journal-title":"J Hepatol"},{"key":"2820_CR11","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1002\/ibd.22901","volume":"18","author":"N Shahidi","year":"2012","unstructured":"Shahidi N, Fu Y-T, Qian H, Bressler B, et al. Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18:2034\u20132042.","journal-title":"Inflamm Bowel Dis"},{"key":"2820_CR12","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","volume":"52","author":"L Carmona","year":"2005","unstructured":"Carmona L, G\u00f3mez-Reino JJ, Rodr\u0131guez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthr Rheum. 2005;52:1766\u20131772.","journal-title":"Arthr Rheum"},{"key":"2820_CR13","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, ACCENT I Study Group. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541\u20131549.","journal-title":"Lancet"},{"key":"2820_CR14","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","volume":"126","author":"P Rutgeerts","year":"2004","unstructured":"Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn\u2019s disease. Gastroenterology. 2004;126:402\u2013413.","journal-title":"Gastroenterology"},{"key":"2820_CR15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2011.11.030","volume":"57","author":"G Papatheodoridis","year":"2012","unstructured":"Papatheodoridis G, Buti M, Cornberg M, et al. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167\u2013185.","journal-title":"J Hepatol"},{"key":"2820_CR16","doi-asserted-by":"crossref","unstructured":"American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005;172:1169\u2013227.","DOI":"10.1164\/rccm.2508001"},{"key":"2820_CR17","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1183\/09031936.02.00261402","volume":"19","author":"JF Broekmans","year":"2002","unstructured":"Broekmans JF, Migliori GB, Rieder HL, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J. 2002;19:765\u2013775.","journal-title":"Eur Respir J"},{"key":"2820_CR18","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/gut.2010.208413","volume":"59","author":"C Loras","year":"2010","unstructured":"Loras C, Gisbert JP, M\u00ednquez M, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut. 2010;59:1340\u20131346.","journal-title":"Gut"},{"key":"2820_CR19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00054725-200111000-00002","volume":"7","author":"L Biancone","year":"2001","unstructured":"Biancone L, Pavia M, Del Vecchio Blanco G, et al. Hepatitis B and C virus infection in Crohn\u2019s disease. Inflamm Bowel Dis. 2001;7:287\u2013294.","journal-title":"Inflamm Bowel Dis"},{"key":"2820_CR20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/ajg.2008.4","volume":"104","author":"C Loras","year":"2009","unstructured":"Loras C, Saro C, Gonzalez-Huix F, et al. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol. 2009;104:57\u201363.","journal-title":"Am J Gastroenterol"},{"key":"2820_CR21","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2004.040675","volume":"53","author":"M Esteve","year":"2004","unstructured":"Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn\u2019s disease patients: need for primary prophylaxis. Gut. 2004;53:1363\u20131365.","journal-title":"Gut"},{"key":"2820_CR22","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/ibd.21147","volume":"16","author":"JB Chevaux","year":"2010","unstructured":"Chevaux JB, Nani A, Oussalah A, et al. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis. 2010;16:916\u2013924.","journal-title":"Inflamm Bowel Dis"},{"key":"2820_CR23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2005.02556.x","volume":"22","author":"S Bargiggia","year":"2005","unstructured":"Bargiggia S, Thorburn D, Anderloni A, et al. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study. Aliment Pharmacol Ther. 2005;22:209\u2013215.","journal-title":"Aliment Pharmacol Ther"},{"key":"2820_CR24","doi-asserted-by":"crossref","unstructured":"Tana SS, Bouwmansa CAM, Rutten FH, et al. Update of the Dutch manual for costing in economic evaluations. Int J Technol Assess. 2012;28:152\u2013158.","DOI":"10.1017\/S0266462312000062"},{"key":"2820_CR25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ibd.21329","volume":"17","author":"BJ Qumseya","year":"2011","unstructured":"Qumseya BJ, Ananthakrishnan AN, Skaros S, et al. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis. 2011;17:77\u201383.","journal-title":"Inflamm Bowel Dis"},{"key":"2820_CR26","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1111\/j.1572-0241.2008.02050.x","volume":"103","author":"AM Schoepfer","year":"2008","unstructured":"Schoepfer AM, Flogerzi B, Falleger S, et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol. 2008;103:2799\u20132806.","journal-title":"Am J Gastroenterol"},{"key":"2820_CR27","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1002\/ibd.21605","volume":"17","author":"E B\u00e9lard","year":"2011","unstructured":"B\u00e9lard E, Semb S, Ruhwald M, et al. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis. 2011;17:2340\u20132349.","journal-title":"Inflamm Bowel Dis"},{"key":"2820_CR28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ibd.21427","volume":"17","author":"P Papay","year":"2011","unstructured":"Papay P, Eser A, Winkler S, et al. Factors impacting the results of interferon-\u03b3 release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:84\u201390.","journal-title":"Inflamm Bowel Dis"},{"key":"2820_CR29","first-page":"1414","volume":"1","author":"F Marra","year":"2008","unstructured":"Marra F, Marra CA, Sadatsafavi M, et al. Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts. Int J Tuberc Lung Dis. 2008;1:1414\u20131424.","journal-title":"Int J Tuberc Lung Dis"},{"key":"2820_CR30","first-page":"847","volume":"3","author":"GW Comstock","year":"1999","unstructured":"Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis. 1999;3:847\u2013850.","journal-title":"Int J Tuberc Lung Dis"},{"key":"2820_CR31","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1056\/NEJMsa021099","volume":"347","author":"K Khan","year":"2002","unstructured":"Khan K, Muennig P, Behta M, et al. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med. 2002;347:1850\u20131859.","journal-title":"N Engl J Med"},{"key":"2820_CR32","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ibd.21007","volume":"16","author":"D Duricova","year":"2010","unstructured":"Duricova D, Pedersen N, Elkjear M, et al. Overall and cause-specific mortality in Crohn\u2019s disease: a meta-analysis of population-based studies. Inflamm Bowel Dis. 2010;16:347\u2013353.","journal-title":"Inflamm Bowel Dis"},{"key":"2820_CR33","unstructured":"Statistics Netherlands. Chances of death tables. Available at http:\/\/statline.cbs.nl . Accessed October 17, 2012."},{"key":"2820_CR34","first-page":"1","volume":"17","author":"SE Roberts","year":"2007","unstructured":"Roberts SE, Williams JG, Yeates D, et al. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn\u2019s disease: record linkage studies. BMJ. 2007;17:1\u20138.","journal-title":"BMJ"},{"key":"2820_CR35","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000097950","volume":"23","author":"SW Polle","year":"2006","unstructured":"Polle SW, Wind J, Ubbink DT, et al. Short-term outcomes after laparoscopic ileocolic resection for Crohn\u2019s disease. Dig Surg. 2006;23:346\u2013357.","journal-title":"Dig Surg"},{"key":"2820_CR36","unstructured":"Dutch Health Care Authority (NZa). http:\/\/www.nza.nl\/137706\/145406\/BR-CU-2015_bijlage_2_med.spec.behandelingen-en-tarieven_2011.xls . Accessed October 17, 2012."},{"key":"2820_CR37","unstructured":"Dutch Health Care Insurance Board (CVZ). http:\/\/www.medicijnkosten.nl\/ . Accessed October 17, 2012."},{"key":"2820_CR38","unstructured":"National Institute of Health and Clinical Excellence (NICE). Guidance on the Use of Infliximab for Crohn\u2019s Disease. London: Technology Appraisal Guidance; 2002."},{"key":"2820_CR39","doi-asserted-by":"crossref","unstructured":"Belderbos TDG, Have M van der, Fidder HH, et al. Screening for opportunistic infections prior to anti-TNF therapy does not preclude the occurence of serious infections. Gastroenterol. 2013;144(Suppl 1):S-409.","DOI":"10.1016\/S0016-5085(13)61507-3"},{"key":"2820_CR40","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/01.MIB.0000159661.55028.56","volume":"11","author":"F Casellas","year":"2005","unstructured":"Casellas F, Arenas J, Baudet J, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis. 2005;11:488\u2013496.","journal-title":"Inflamm Bowel Dis"},{"key":"2820_CR41","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1524-4733.2007.00297.x","volume":"11","author":"AR Levy","year":"2008","unstructured":"Levy AR, Kowdley KV, Iloeje U, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health. 2008;11:527\u2013538.","journal-title":"Value Health"},{"key":"2820_CR42","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/j.1524-4733.2008.00355.x","volume":"11","author":"N Guo","year":"2008","unstructured":"Guo N, Marra CA, Marra F, et al. Health state utilities in latent and active tuberculosis. Value Health. 2008;11:1154\u20131161.","journal-title":"Value Health"},{"key":"2820_CR43","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2036.2008.03709.x","volume":"28","author":"J Lindsay","year":"2008","unstructured":"Lindsay J, Punekar YS, Morris J, et al. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn\u2019s disease\u2013modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther. 2008;28:76\u201387.","journal-title":"Aliment Pharmacol Ther"},{"key":"2820_CR44","unstructured":"Ara R, Wailoo A. NICE DSU technical support document 12: the use of health state utility values in decision models. School of Health and Related Research, University of Sheffield, UK; 2011."},{"key":"2820_CR45","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1586\/14737167.4.3.247","volume":"4","author":"JM Bos","year":"2004","unstructured":"Bos JM, Postma MJ. Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for cost-effectiveness? Expert Rev Pharmacoecon Outcomes Res. 2004;4:247\u2013250.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2820_CR46","unstructured":"Busschbach, JJ, van en Delwel GO. Het pakketprincipe kosteneffectiviteit achtergrondstudie ten behoeve van de \u2018appraisal\u2019 fase in pakketbeheer. CVZ, Diemen; 2010."},{"key":"2820_CR47","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","volume":"30","author":"JJ Ott","year":"2012","unstructured":"Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212\u20132219.","journal-title":"Vaccine"},{"key":"2820_CR48","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","volume":"149","author":"M Pal","year":"2008","unstructured":"Pal M, Zwerling A, Menzies D, et al. Systematic review: T-Cell\u2013based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149:177\u2013184.","journal-title":"Ann Intern Med"},{"key":"2820_CR49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1164\/ajrccm.159.1.9801120","volume":"159","author":"D Menzies","year":"1999","unstructured":"Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion and reversion. Am J Respir Crit Care Med. 1999;159:15\u201321.","journal-title":"Am J Respir Crit Care Med"},{"key":"2820_CR50","first-page":"1414","volume":"1","author":"F Marra","year":"2008","unstructured":"Marra F, Marra CA, Sadatsafavi M, et al. Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts. Int J Tuberc Lung Dis. 2008;1:1414\u20131424.","journal-title":"Int J Tuberc Lung Dis"},{"key":"2820_CR51","doi-asserted-by":"crossref","unstructured":"Metz A, Elliot T, Hull B, et al. Cost analysis of screening according to EXTENSIVE guidelines for prevention of opportunistic infections in infliximab-treated IBD patients [Abstract]. Gut. 2011;60:PA142.","DOI":"10.1136\/gut.2011.239301.301"},{"key":"2820_CR52","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.2011.35.1635","volume":"29","author":"FL Day","year":"2011","unstructured":"Day FL, Karnon J, Rischin D. Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J Clin Oncol. 2011;29:3270\u20133277.","journal-title":"J Clin Oncol"},{"key":"2820_CR53","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2011.40.7510","volume":"30","author":"U Zurawska","year":"2012","unstructured":"Zurawska U, Hicks LKH, Woo G, et al. Hepatitis B screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol. 2012;30:3167\u20133173.","journal-title":"J Clin Oncol"},{"key":"2820_CR54","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/jama.281.11.1014","volume":"281","author":"CM Nolan","year":"1999","unstructured":"Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA. 1999;281:1014\u20131018.","journal-title":"JAMA"},{"key":"2820_CR55","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/ajg.2009.733","volume":"105","author":"SK Wasan","year":"2010","unstructured":"Wasan SK, Baker SE, Skolnik PR, et al. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol. 2010;105:1231\u20131238.","journal-title":"Am J Gastroenterol"},{"key":"2820_CR56","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/ajg.2012.79","volume":"107","author":"JP Gisbert","year":"2012","unstructured":"Gisbert JP, Villagrasa JR, Rodr\u00edguez-Nogueiras A, et al. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1460\u20131466. doi: 10.1038\/ajg.2012.79 .","journal-title":"Am J Gastroenterol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-013-2820-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-013-2820-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-013-2820-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T19:44:07Z","timestamp":1559245447000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-013-2820-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,15]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["2820"],"URL":"https:\/\/doi.org\/10.1007\/s10620-013-2820-9","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,15]]}}}